SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amgen Inc. (AMGN)

NEW YORK, May 23, 2017

The investigation concerns whether Amgen and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On May 22, 2017, Amgen revealed that Evenity, its osteoporosis medicine, raised heart safety concerns that will lead to a delay in securing approval in the United States. According to Amgen's data, a larger percentage of patients who took the drug suffered serious cardiovascular side effects after a year, compared to those who took an older approved medicine. Following this news, Amgen stock dropped $3.49 per share or 2.3%, to close at $153.02 on May 22, 2017.

If you are aware of any facts relating to this investigation, or purchased shares of Amgen, you can assist this investigation by visiting the firm's site: www.bgandg.com/amgn. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com